Where next for Acacia Pharma on positive PhIII PONV data?
This article was originally published in Scrip
Executive Summary
Private UK company Acacia Pharma is hoping to return dopamine antagonists to the arsenal of drugs available for post-operative nausea and vomiting (PONV) following positive top-line results from two Phase III studies of its lead product APD421.
You may also be interested in...
Acacia Pharma's Antiemetic Baremsis A Step Closer to US Filing
Acacia Pharma has taken another step towards filing its post-operative nausea and vomiting treatment Baremsis in the US with a second Phase III trial, this time in the treatment, rather than prevention, of the condition.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.